deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT01795313

Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod

Immunotherapy for Recurrent Ependymomas in Children Using Human Leukocyte Antigen (HLA)-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod

Sponsor: James Felker

Conditions Ependymoma
Interventions HLA-A2 restricted synthetic tumor antigen Imiquimod enzyme-linked immunosorbent assay flow cytometry immunohistochemistry staining method laboratory biomarker analysis
Updated 17 times since 2017 Last updated: Feb 3, 2026 Started: Aug 31, 2012 Primary completion: Dec 3, 2025 Completion: Dec 3, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Closed supratentorial arm prematurely secondary to lack of enrollment

Other Ependymoma trials with similar outcome

Browse all Ependymoma trials

Listed as NCT01795313, this PHASE1 trial focuses on Ependymoma and remains terminated or withdrawn. Sponsored by James Felker, it has been updated 17 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Feb 2018 · 10 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Feb 2019 · 7 months · monthly snapshot~Feb 2019 – ~Jan 2020 · 11 months · monthly snapshot~Jan 2020 – ~Sep 2020 · 8 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Nov 2022 · 14 months · monthly snapshot~Nov 2022 – ~Dec 2023 · 13 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Feb 2026 · 13 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

17 versions recorded

  1. Feb 2026 — Present [monthly]

    Terminated PHASE1

    Status: Recruiting → Terminated

  2. Jan 2025 — Feb 2026 [monthly]

    Recruiting PHASE1

  3. Sep 2024 — Jan 2025 [monthly]

    Recruiting PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  5. Dec 2023 — Jul 2024 [monthly]

    Recruiting PHASE1

▶ Show 12 earlier versions

  1. Nov 2022 — Dec 2023 [monthly]

    Recruiting PHASE1

  2. Sep 2021 — Nov 2022 [monthly]

    Recruiting PHASE1

  3. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  4. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

    Phase: NA → PHASE1

  5. Jan 2020 — Sep 2020 [monthly]

    Recruiting NA

  6. Feb 2019 — Jan 2020 [monthly]

    Recruiting NA

  7. Jul 2018 — Feb 2019 [monthly]

    Recruiting NA

  8. Jun 2018 — Jul 2018 [monthly]

    Recruiting NA

  9. Feb 2018 — Jun 2018 [monthly]

    Recruiting NA

  10. Apr 2017 — Feb 2018 [monthly]

    Recruiting NA

  11. Feb 2017 — Apr 2017 [monthly]

    Recruiting NA

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting NA

    First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • James Felker
  • National Cancer Institute (NCI)
  • Solving Kids' Cancer
Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations